---
title: "Azetukalner (XEN1101) in Focal onset seizures: Clinical evidence"
description: "Formulary evidence on Azetukalner (XEN1101) in Focal onset seizures: Clinical evidence. Covers X-TOLE, X-TOLE2, X-TOLE3, and X-TOLE4. 152 evidence topics quoted from 22 sources."
canonical: "https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/clinical-evidence"
published: "2026-09-21T21:41:53-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Azetukalner (XEN1101) in Focal onset seizures: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 X-TOLE

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Trial objective: efficacy and safety of a KV7.2 and KV7.3 opener in focal onset seizures

> “To evaluate the efficacy and safety of XEN1101, a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener, in the treatment of focal-onset seizures (FOSs).”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.1-2"></a>

###### Primary and secondary objectives stated by the investigators

> “The primary objectives of X-TOLE were to assess the efficacy, safety, and tolerability of 3 doses of XEN1101 in comparison with placebo on FOS frequency in adults with focal epilepsy. Secondary objectives included an assessment of 50% responder rates and a characterization of the effects of each XEN1101 dose on seizure frequency in weekly intervals during the double-blind phase (DBP) to allow a determination of the speed of onset and durability of response.”
> “Additional exploratory analyses reported herein include a time-to-event analysis (time for seizure count to reach the baseline monthly count) and an assessment of the effects of XEN1101 on overall health status as reported by the patients and their caregivers.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.1-3"></a>

###### Registry statement of purpose

> “The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Summary: sites, countries, and enrollment period

The registry record for NCT03796962 lists 95 investigative sites in 9 countries: the United States (54 sites), Spain (15), Germany (9), Italy (7), the United Kingdom (4), Canada (3), Georgia (1), Moldova (1), and Ukraine (1). The registry gives an actual study start date of January 30, 2019, an actual primary completion date of September 2, 2021, and an estimated completion date of October 2028 for the continuing open-label extension. The primary publication reports 97 trial sites in North America and Europe, while the open-label extension publication reports 95 sites. The sponsor is Xenon Pharmaceuticals Inc., and the protocol identifier is XPF-008-201.

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962); [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/); [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.2-2"></a>

###### Number of sites and regions

> “Adults experiencing 4 or more monthly FOSs while receiving stable treatment (1-3 ASMs) were enrolled at 97 sites in North America and Europe.”
> “Patients were enrolled in North America (39.1%) or Europe (60.9%).”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.2-3"></a>

###### Site count reported in the open-label extension publication

> “The X-TOLE study was conducted at 95 sites across North America and Europe (NCT03796962; EudraCT, 2018–003221-29).”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.2-4"></a>

###### Study dates

> “This phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging adjunctive trial investigated XEN1101 over an 8-week treatment period from January 30, 2019, to September 2, 2021, and included a 6-week safety follow-up.”
> “The present article reports findings from the completed DBP of the study, including the first patient randomized in June 2019 through the last patient treated in August 2021.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Randomized, double-blind, placebo-controlled, dose-ranging adjunctive design

> “This was a multicenter, randomized, double-blind, parallel-group, dose-ranging, placebo-controlled adjunctive-therapy clinical trial in which XEN1101 was administered once daily with food as a 10-, 20-, or 25-mg oral capsule.”
> “Patients meeting eligibility criteria were randomized for an 8-week DBP to 1 of 3 active treatment groups or placebo in a 2:1:1:2 ratio: 25, 20, or 10 mg of XEN1101 or placebo.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.3-2"></a>

###### Registry description of design, masking, and phases

> “The XEN1101 Phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled, multicenter study with an optional open-label extension (OLE) to evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive treatment in adult patients aged 18 to 75 years diagnosed with focal epilepsy. Approximately 300 patients will be randomized in a blinded manner to one of three active treatment groups or placebo in a 2:1:1:2 fashion (XEN1101 25 mg : 20 mg : 10 mg : Placebo). After screening, patients will have 8 weeks of baseline to assess frequency of seizures, followed by 8 weeks of treatment and a 6-week post treatment follow-up period.”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="topic-3.1.1.3-3"></a>

###### Baseline period and electronic seizure diary

> “Key eligibility criteria included experiencing 4 or more countable FOSs on average per month, recorded from home in an e-diary during a prospective 8-week baseline period, while receiving stable treatment of between 1 and 3 ASMs. The e-diary stored daily seizure and treatment adherence information that was electronically transmitted to the database. Central surveillance of e-diary functionality and patient adherence, as well as clinical status, was used in addition to patient monitoring by participating sites.”
> “Extensions of the baseline period up to 20 weeks were allowed if COVID-19 pandemic-related site access restrictions prevented patients from attending site visits.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.3-4"></a>

###### Randomization method and stratification

> “To ensure balanced distribution across groups, randomization was stratified by background use of CYP3A4 inducer medications (eg, carbamazepine, eslicarbazepine acetate, oxcarbazepine, phenytoin, topiramate, or phenobarbital). Randomization was implemented centrally in the Medidata Rave Randomization and Trial Supply Management system, using a dynamic allocation randomization algorithm (nondeterministic).”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.3-5"></a>

###### Follow-up and total study duration for participants not entering the extension

> “Patients who did not participate in the open-label extension (OLE) had a follow-up visit 1 week posttreatment and a final follow-up visit 6 weeks following the last dose. The total study duration per randomized patient (for those not entering the OLE) was approximately 26 weeks (6 months) from screening to follow-up.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.3-6"></a>

###### Open-label extension design

> “Participants who completed the DBP with a minimum of 80% study medication compliance and no important protocol deviations were eligible to enter the OLE phase, during which participants from all DBP arms began treatment with azetukalner 20 mg taken once daily with food (Figure 1). Azetukalner dose adjustments and changes in concomitant ASMs were allowed during the OLE. Assessments occurred at week 3 in the OLE (study day 77, week 11 from randomization) and at 3-month intervals thereafter for the first year. After the first year, on-site visits occurred at 6-month intervals, with teleconferences at 3 months between each on-site visit. The OLE phase is scheduled for completion after 378 weeks (7 years) of treatment, and no participant has yet completed the study.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.3-7"></a>

###### Extension dose stated in the registry record

> “An OLE will be available to eligible patients who complete the DBP. All patients will receive a 20 mg daily dose of XEN1101 during this extension period.”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="topic-3.1.1.3-8"></a>

###### Reporting guideline and ethics oversight

> “This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Age range and countable seizure types

> “Adults aged 18 to 75 years with FOSs provided written informed consent and were enrolled; participants did not receive financial compensation.”
> “The types of countable focal seizures assessed included focal aware seizures with motor signs, focal seizures with impaired awareness, and focal seizures evolving to bilateral tonic-clonic seizures.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.4-2"></a>

###### Seizure frequency and background antiseizure medication requirements

> “Participants needed to be 18–75 years old with a diagnosis of focal epilepsy per International League Against Epilepsy criteria”
> “for ≥2 years, experience ≥4 countable FOS per month during an 8-week minimum baseline period, and receive stable treatment with 1–3 ASMs.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.4-3"></a>

###### Key inclusion criteria as registered

> “Diagnosis (≥2 years) of focal epilepsy according to the International League Against Epilepsy [ILAE] Classification of Epilepsy (2017)”
> “Treatment with a stable dose of 1 to 3 allowable current AEDs for at least one month prior to screening, during baseline, and throughout the duration of the DBP”
> “Able to keep accurate seizure diaries”
> “Prior neuroimaging within the last 10 years and documentation is available”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="topic-3.1.1.4-4"></a>

###### Key exclusion criteria: seizure type and epilepsy syndrome

> “History of pseudoseizures, psychogenic seizures, primary generalized seizure, or focal aware non-motor seizures only”
> “Presence or previous history of Lennox-Gastaut syndrome”
> “Seizures secondary to other diseases or conditions”
> “History of repetitive seizures within the last 12 months where the individual seizures cannot be counted”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="topic-3.1.1.4-5"></a>

###### Key exclusion criteria: prior ezogabine, vigabatrin, and felbamate exposure

> “History of skin or retinal pigment epithelium abnormalities caused by ezogabine”
> “Past use of vigabatrin without stable visual fields tested twice over the 12 months after the last dose of vigabatrin (concomitant use of vigabatrin is not allowed)”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="topic-3.1.1.4-6"></a>

###### Key exclusion criteria: psychiatric, cardiac, and other medical conditions

> “Schizophrenia and other psychotic disorders, or active suicidal plan/intent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt”
> “Have had multiple drug allergies or a severe drug reaction to an AED(s), including dermatological (e.g., Stevens-Johnson syndrome), hematological, or organ toxicity reactions”
> “Current use of a ketogenic diet”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Dose groups, formulation, and administration with food

> “Patients were randomized 2:1:1:2 to receive XEN1101, 25, 20, or 10 mg, or placebo with food once daily for 8 weeks. Dosage titration was not used.”
> “XEN1101 was administered as a once-daily adjunctive treatment in capsule formulation by mouth. Because the oral bioavailability of XEN1101 is enhanced by coadministration with food, patients were instructed to take the study medication with the evening meal.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.5-2"></a>

###### Pharmacokinetic rationale for once-daily dosing without titration

> “The pharmacokinetic properties of XEN1101, including a long terminal elimination half-life (approximately 10 days), support once-daily oral dosing without the need for titration at initiation of dosing or tapering at termination of dosing.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.5-3"></a>

###### Concomitant antiseizure medications during the double-blind phase

> “A total of 8.9% of the patients received 1 stable ASM at baseline and concomitantly throughout the DBP of the study, 40.6% of the patients received 2, and 50.5% of the patients received 3. Patients had tried and stopped a median of 6 previous ASMs before study entry. More than half of the patients (57.8%) were taking a CYP3A4 inducer at baseline.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.5-4"></a>

###### Requirement for stable background medication

> “In order to be included in the study, patients must already be treated with a stable dose of 1 to 3 allowable current anti-epileptic drugs for at least one month prior to screening, during baseline, and throughout the double-blind portion (DBP) of the study.”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Median Percent Change in Monthly Focal Onset Seizure Frequency as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint and safety measures

> “The primary efficacy end point was the median percent change from baseline in monthly FOS frequency. Treatment-emergent adverse events (TEAEs) were recorded and comprehensive laboratory assessments were made. Modified intention-to-treat analysis was conducted.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.6.1-2"></a>

###### Registered primary outcome measure

> “Median percent change in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="topic-3.1.1.6.1-3"></a>

###### Registered secondary outcome measures

> “Responders are defined as patients experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline to DBP”
> “Percent change from baseline in focal seizure frequency at Month 1 and Month 2 in the DBP”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="topic-3.1.1.6.1-4"></a>

###### Safety assessments

> “Safety was assessed as severity and frequency of treatment-emergent adverse events (TEAEs) and serious AEs, clinically significant changes in laboratory findings, and other measures including electrocardiography.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.6.1-5"></a>

###### Long-term outcome measures assessed in the open-label extension

> “Long-term seizure outcomes included median percentage change (MPC) in monthly (28 days) FOS frequency from the double-blind phase (DBP) baseline and achievement of ≥50%, ≥75%, ≥90%, and 100% seizure reductions.”
> “Long-term safety was assessed by frequency and severity of TEAEs and serious adverse events (SAEs). Additional safety outcomes included findings from physical, neurologic, and ophthalmoscopy examinations, clinically significant laboratory findings, vital signs, 12-lead electrocardiograph, and urological symptoms, as well as an increase in suicide risk via the Columbia-Suicide Severity Rating Scale.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.6.1-6"></a>

###### Dose-response objective and analysis model

> “The primary study objective was to assess the dose-response activity of XEN1101 in reducing monthly (28-day) FOS frequency, and the primary end point assessed the monotonic dose-response relationship between the XEN1101 active dose groups compared with placebo, based on a ranked analysis of covariance model.”
> “The analysis of percent change from baseline was calculated based on monthly (28 days) FOS frequency.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.6.1-7"></a>

###### Unmet need that the endpoint is intended to capture

> “Many individuals with epilepsy continue to experience seizures despite treatment with available antiseizure medications (ASMs). There is therefore a need for more efficacious ASMs, and particularly for ones that confer greater seizure reduction or seizure freedom.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.6.1-8"></a>

###### Responder rate as the accompanying secondary efficacy criterion

> “Another widely used efficacy endpoint for evaluating ASM efficacy is the percentage of patients with a ≥50% reduction in seizure frequency during a given treatment period compared with baseline, known as the RR50.”

Source: [Porter et al. (2023)](https://aesnet.org/abstractslisting/the-impact-of-disease-severity-on-responder-rates-in-a-phase-2b-study-of-xen1101-a-potent-selective-potassium-channel-opener-in-adults-with-focal-epilepsy-x-tole)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned sample size and power

> “The sample size of 300 participants in the DBP was chosen to provide at least 80% power at a 2-sided .05-level for detecting a monotonic dose response.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned randomization ratio

> “Approximately 300 patients will be randomized in a blinded manner to one of three active treatment groups or placebo in a 2:1:1:2 fashion (XEN1101 25 mg : 20 mg : 10 mg : Placebo).”

Source: [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)

<a id="topic-3.1.1.7.1-3"></a>

###### Participants randomized and analyzed

> “A total of 325 patients who were randomized and treated were included in the safety population (Figure 1B) and 323 patients in the modified intention-to-treat population were included in the efficacy analyses.”
> “A total of 325 patients who were randomized and treated were included in the safety analysis; 285 completed the 8-week double-blind phase.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants by treatment group

> “A total of 325 participants were randomized in the X-TOLE study (placebo, n = 114; 10 mg group, n = 46; 20 mg group, n = 51; 25 mg group, n = 114).”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.7.1-5"></a>

###### Participants screened and randomized

> “A total of 530 patients were screened and 325 patients randomized and treated.”

Source: [French et al. (2021)](https://aesnet.org/abstractslisting/phase-2b-efficacy-and-safety-of-xen1101--a-novel-potassium-channel-modulator--in-adults-with-focal-epilepsy-(x-tole))

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Modified intention-to-treat population used for efficacy

> “All efficacy analyses were performed using the modified intention-to-treat population (randomized and treated patients with at least 1 seizure diary entry recorded post treatment).”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.7.2-2"></a>

###### Statistical testing and estimation

> “Both 1-sided and 2-sided tests are reported, with significance threshold set at P < .05. The Hodges-Lehmann estimate for each dose vs placebo was calculated accompanied by the associated 2-sided 90% and 95% CIs. Statistical analysis was conducted with SAS, version 9.4 or higher (SAS Institute Inc).”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.7.2-3"></a>

###### Open-label extension analysis populations

> “The MPC analysis was conducted for the overall group, for a numerically constant cohort group, which consisted of participants who were treated for at least 24 months in the OLE and for those who were continuing in the study at data cutoff.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Completion of the double-blind phase and entry into the open-label extension

> “A total of 285 patients completed the DBP of the trial. Of these, 275 individuals (96.5%) entered the OLE to evaluate the long-term safety, tolerability, and effectiveness of XEN1101.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.1-2"></a>

###### Overall dropout during the double-blind phase

> “The overall dropout was 12.3%; 96.5% of study completers rolled over into the OLE.”

Source: [French et al. (2021)](https://aesnet.org/abstractslisting/phase-2b-efficacy-and-safety-of-xen1101--a-novel-potassium-channel-modulator--in-adults-with-focal-epilepsy-(x-tole))

<a id="topic-3.1.1.8.1-3"></a>

###### Discontinuation due to treatment-emergent adverse events by dose group

> “Discontinuation associated with TEAEs occurred in 3.5% of patients receiving placebo, 2.2% of patients receiving 10 mg, 13.7% of patients receiving 20 mg, and 15.8% of patients receiving 25 mg.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.1-4"></a>

###### Open-label extension disposition at the 24-month interim analysis

> “As of September 5, 2023 (cutoff date for the current interim analysis), 152 (55.3%) remained in the study, 182 (66%) had been treated in the OLE for ≥12 months, and 165 (60%) had been treated for ≥24 months. The mean and median duration of treatment were 662 days (21.8 months) and 799 days (26.3 months), respectively (range, 0.1–46.6 months). Of all participants who entered the OLE (N = 275), 67 participants (24.4%) had dose reductions. The most common reasons given for discontinuation were lack of efficacy (n = 38, 13.8%), AEs (n = 33, 12.0%), and study withdrawal by the participant (n = 33, 12.0%).”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.8.1-5"></a>

###### Open-label extension disposition at the April 2025 data cut

> “As of the current data cut (April 1, 2025), 182 participants had received treatment for ≥12 months, 165 for ≥24 months, and 135 for ≥42 months; 123 (44.7%) are ongoing. As of the cutoff date, the OLE has generated >700 participant-years of safety data. The most common reasons for discontinuation were lack of efficacy (n=50 participants, 18.2%), withdrawal by participant (n=46, 16.7%), and AEs (n=36, 13.1%).”

Source: [French et al. (2025b)](https://aesnet.org/abstractslisting/long-term-safety-and-efficacy-of-azetukalner-a-novel-potent-kv7-potassium-channel-opener-in-adults-with-focal-epilepsy-42-month-interim-analysis-of-the-ongoing-7-year-x-tole-open-label-extension)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographic characteristics of the randomized population

> “Patient baseline demographic and other characteristics are presented in Table 1 and were generally comparable across groups at study entry. Mean (SD) patient age was 40.8 (13.3) years, 168 (51.7%) were female, and 298 (91.7%) identified their race as White.”
> “The mean (SD) body mass index was 26.8 (5.2) (calculated as weight in kilograms divided by height in meters squared). Patient mean (SD) age at the time of disease onset was 17.1 (13.6) years, with a range from 0 to 61 years.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.2-2"></a>

###### Baseline seizure frequency and treatment history

> “A total of 8.9% of the patients received 1 stable ASM at baseline and concomitantly throughout the DBP of the study, 40.6% of the patients received 2, and 50.5% of the patients received 3. Patients had tried and stopped a median of 6 previous ASMs before study entry. More than half of the patients (57.8%) were taking a CYP3A4 inducer at baseline. The median baseline FOS frequency was 13.5 (IQR, 7.9-30.3) per month.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.2-3"></a>

###### Baseline characteristics by treatment group

| Characteristic | Placebo (n = 114) | XEN1101, 10 mg (n = 46) | XEN1101, 20 mg (n = 51) | XEN1101, 25 mg (n = 114) | Total (N = 325) |
| --- | --- | --- | --- | --- | --- |
| Age, mean (SD), y | “42.9 (13.7)” | “40.0 (12.1)” | “41.7 (13.6)” | “38.7 (13.1)” | “40.8 (13.3)” |
| Female | “61 (53.5)” | “27 (58.7)” | “26 (51.0)” | “54 (47.4)” | “168 (51.7)” |
| Male | “53 (46.5)” | “19 (41.3)” | “25 (49.0)” | “60 (52.6)” | “157 (48.3)” |
| Europe | “67 (58.8)” | “31 (67.4)” | “32 (62.7)” | “68 (59.6)” | “198 (60.9)” |
| North America | “47 (41.2)” | “15 (32.6)” | “19 (37.3)” | “46 (40.4)” | “127 (39.1)” |
| BMI, mean (SD) | “27.3 (5.4)” | “26.6 (5.1)” | “26.7 (5.0)” | “26.5 (5.1)” | “26.8 (5.2)” |
| Age at disease onset, mean (SD), y | “19.2 (14.7)” | “19.8 (14.8)” | “14.1 (12.1)” | “15.3 (12.1)” | “17.1 (13.6)” |
| CYP3A4 inducer use: Yes | “69 (60.5)” | “25 (54.3)” | “29 (56.9)” | “65 (57.0)” | “188 (57.8)” |
| Background ASM use: 1 | “12 (10.5)” | “4 (8.7)” | “2 (3.9)” | “11 (9.6)” | “29 (8.9)” |
| Background ASM use: 2 | “46 (40.4)” | “18 (39.1)” | “20 (39.2)” | “48 (42.1)” | “132 (40.6)” |
| Background ASM use: 3 | “56 (49.1)” | “24 (52.2)” | “29 (56.9)” | “55 (48.2)” | “164 (50.5)” |
| No. of prestudy ASMs failed, median (IQR) | “6.0 (4.0-8.0)” | “5.0 (4.0-9.0)” | “6.0 (4.0-9.0)” | “6.0 (3.0-9.0)” | “6.0 (4.0-9.0)” |

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.2-4"></a>

###### Baseline characteristics of the open-label extension population

| Characteristic | Open-label extension population (n = 275) |
| --- | --- |
| Age at study entry, mean (SD), years | “41.1 (13.3)” |
| Female | “138 (50.2)” |
| White | “250 (90.9)” |
| Black | “11 (4.0)” |
| Europe | “166 (60.4)” |
| North America | “109 (39.6)” |
| Age at epilepsy onset, mean (SD), years | “18.1 (13.8)” |
| Baseline seizure rate per month, median (IQR) | “13.5 (7.9, 30.3)” |
| Number of ASMs tried and discontinued before study entry, mean (SD) | “6.5 (3.7)” |
| Background ASM use: 3 | “144 (52.4)” |
| CYP3A4 inducer use, n (%) | “160 (58.2)” |

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint: dose response and median percent reduction in monthly focal onset seizure frequency

> “A robust dose response for seizure reduction was present (primary dose-response test: P < .001) (Table 2). There was a greater reduction in monthly FOS frequency from baseline during the treatment period for patients receiving XEN1101 compared with those receiving placebo, and the effect was statistically significant for each dose. The median percent reduction and associated 2-sided P values from baseline in monthly FOS frequency was 52.8% (P < .001 vs placebo; IQR, −80.4% to −16.9%) in the 25-mg group, 46.4% (P < .001 vs placebo; IQR, −76.7% to −14.0%) in the 20-mg group, and 33.2% (P = .04 vs placebo; IQR, −61.8% to 0.0%) in the 10-mg group, compared with 18.2% (IQR, −37.3% to 7.0%) in the placebo group (Table 2 and Figure 2A).”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.3-2"></a>

###### Efficacy of azetukalner in the double-blind phase

| Variable | Placebo (n = 114) | XEN1101, 10 mg (n = 46) | XEN1101, 20 mg (n = 51) | XEN1101, 25 mg (n = 112) |
| --- | --- | --- | --- | --- |
| Monthly seizure frequency in baseline, median (IQR) | “13.4 (8.0 to 30.1)” | “17.4 (8.0 to 55.6)” | “14.5 (7.5 to 36.4)” | “12.8 (8.4 to 24.6)” |
| Monthly seizure frequency in the double-blind phase, median (IQR) | “10.5 (5.4 to 25.1)” | “10.9 (3.5 to 41.2)” | “5.2 (3.0 to 24.9)” | “5.3 (2.5 to 13.6)” |
| Percent change from baseline to the double-blind phase, median (IQR) | “−18.2 (−37.3 to 7.0)” | “−33.2 (−61.8 to 0.0)” | “−46.4 (−76.7 to −14.0)” | “−52.8 (−80.4 to −16.9)” |
| P value for pairwise comparison vs placebo (2-sided) | “NA” | “.04” | “<.001” | “<.001” |
| P value for primary dose response (2-sided) | “<.001” | “NA” | “NA” | “NA” |
| Responder rates, OR vs placebo (95% CI) | “NA” | “2.48 (1.05 to 5.84)” | “4.78 (2.18 to 10.52)” | “7.30 (3.77 to 14.10)” |
| CGI-C at least much improved, % of patients | “22.8” | “23.9” | “33.3” | “46.4” |
| PGI-C at least much improved, % of patients | “21.9” | “34.8” | “37.3” | “42.9” |

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.3-3"></a>

###### Responder rates and seizure freedom during the double-blind phase

> “Responders were defined as those who achieved a 50% or greater reduction from baseline in monthly FOS frequency. There was a dose-dependent increase in the number of responders (Figure 2B). The percentage and associated 2-sided P values vs placebo of patients who were responders was 54.5% (P < .001 vs placebo) in the 25-mg group, 43.1% (P < .001 vs placebo) in the 20-mg group, and 28.3% (P = .04 vs placebo) in the 10-mg group, compared with 14.9% in the placebo group (Figure 2B). Seizure freedom rates, derived from the median percent change at 100% reduction during the 8-week treatment period, in all observed patients were 6.3% in the 25-mg group, 7.8% in the 20-mg group, 2.2% in the 10-mg group, and 1.8% in the placebo group. In the completers, the rates of seizure freedom were 4.5% in the 25-mg group, 3.9% in the 20-mg group, 2.2% in the 10-mg group, and 1.8% in the placebo group (Figure 2C).”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.3-4"></a>

###### Sponsor-reported primary and responder analyses

> “The median percent reduction in monthly focal seizure frequency was 52.8% in the XEN1101 25 mg group, 46.4% in the XEN1101 20 mg group, and 33.2% in the XEN1101 10 mg group compared to 18.2% in the placebo group. Statistical significance was achieved for all dose groups compared to placebo with 2-sided p-values of p<0.001 for 25 mg vs. placebo, p<0.001 for 20 mg vs. placebo, and p=0.035 for 10 mg vs. placebo.”
> “The percentage of subjects who achieved a >50% reduction in monthly focal seizures was 54.5% in the XEN1101 25 mg group, 43.1% in the XEN1101 20 mg group, and 28.3% in the XEN1101 10 mg group compared to 14.9% in the placebo group. Statistical significance was achieved for all dose groups compared to placebo with 2-sided p-values of p<0.001 for 25 mg vs. placebo, p<0.001 for 20 mg vs. placebo, and p=0.037 for 10 mg vs placebo.”

Source: [Xenon Pharmaceuticals X-TOLE topline release (2021)](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-announces-positive-topline-results-phase)

<a id="topic-3.1.1.8.3-5"></a>

###### Onset of response at week 1

> “The onset of response was rapid as assessed by post hoc analysis of the percentage of patients who were responders at the end of the first week. The percentages were 53.6% (P < .001 vs placebo) in the 25-mg group, 47.1% (P < .05 vs placebo) in the 20-mg group, and 43.5% (P < .05 vs placebo) in the 10-mg group, compared with 28.1% of patients receiving placebo. Analysis of the reductions in median weekly FOS frequencies at the end of the first week also demonstrated rapid onset: there was a reduction of 55.4% (P < .001 vs placebo) in the 25-mg group, 41.5% (P = .04 vs placebo) in the 20-mg group, and 39.1% (P < .01 vs placebo) in the 10-mg group, compared with 20.2% in the placebo group. The response in the 20- and 25-mg groups was sustained throughout the study (Figure 2D).”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.3-6"></a>

###### Post hoc week 1 analysis presented at a congress

> “At week 1, XEN1101 demonstrated a reduction of 39.1% (p=0.002), 41.5% (p=0.039) and 55.4% (p< 0.001) in the 10, 20, and 25 mg groups, respectively, from baseline in median weekly FOS compared to placebo (20.2%). At week 1, RR50 was 43.5% (p=0.034), 47.1% (p=0.015) and 53.6% (p< 0.001) for 10, 20 and 25 mg, respectively, compared to placebo (28.1%).”

Source: [Kenney et al. (2022)](https://aesnet.org/abstractslisting/rapid-onset-of-efficacy-of-xen1101--a-novel-potassium-channel-opener--in-adults-with-focal-epilepsy--results-from-a-phase-2b-study-(x-tole))

<a id="topic-3.1.1.8.3-7"></a>

###### Exploratory endpoint: time to reach baseline monthly seizure count

> “The exploratory end point of time to reach baseline monthly FOS count was also assessed (Figure 2E). Patients in the placebo group reached their baseline monthly FOS count by a median of 4.7 weeks, whereas patients in the 10-mg XEN1101 group did not reach their monthly baseline FOS count until approximately week 6, and those in the 20-mg group until a median of 7.4 weeks. The median time to baseline FOS count was more than 8 weeks in the 25-mg group, because most patients did not reach this end point at the end of the 8-week treatment period.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.3-8"></a>

###### Open-label extension: median percent change in monthly focal onset seizure frequency

> “For ongoing OLE participants, monthly MPC reductions from the DBP baseline in FOS frequency improved over time from 61% (n = 266) at month 1, with MPC reductions (lower, upper quartile) from baseline of 68.5% (95.4, 37.0) at 3 months and 73.1% (100, 40.7) at 6 months (Figure 2A). At months 12, 18, and 24, the MPC reductions were 80.2% (100.0, 60.0), 83.0% (100, 50.9), and 83.2% (100, 53.2), respectively. For the constant cohort (treatment ≥24 months), the reductions in monthly MPC from baseline were 73.8% (100.0, 47.1) at 3 months and 78.8% (100.0, 49.2) at 6 months (Figure 2B). At months 12, 18, and 24, the constant cohort reductions were 82.1% (100.0, 62.8), 83.0% (100, 51.4) and 83.3% (100.0, 53.6), respectively.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.8.3-9"></a>

###### Open-label extension: responder rates and seizure freedom at 24 months

> “In the OLE, 155 (56.4%) and 122 (44.4%) participants achieved a ≥50% seizure reduction for any consecutive ≥6-and ≥12-month period, respectively”
> “Seizure reductions of ≥90% were achieved by 78 (28.4%) participants for any consecutive ≥6-month period and 54 (19.6%) participants for any consecutive ≥12-month period.”
> “a ≥50% seizure reduction was achieved by 138 participants (83.6%) for any consecutive ≥6-month period and 115 (69.7%) participants for any consecutive ≥12-month period”
> “Seizure reductions of ≥90% for this population were achieved by 72 (43.6%) participants for any consecutive ≥6-month period and 52 (31.5%) participants for any consecutive ≥12-month period.”
> “Seizure freedom (100% reduction in monthly FOS frequency) in the overall population was achieved by 61 (22.2%) and 41 (14.9%) participants for any consecutive ≥6-month period and ≥12-month period, respectively (Figure 3C). For participants who had been treated for ≥24 months in the OLE, seizure freedom was achieved by 57 (34.5%) participants for any consecutive ≥6-month period and 39 (23.6%) participants for any consecutive ≥12-month period. In ongoing participants (n = 152), 19.1% (29/152) experienced seizure freedom for ≥12 months since the last visit.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.8.3-10"></a>

###### Open-label extension: summary of long-term efficacy

> “Azetukalner 20 mg once-daily with food yielded long-term efficacy in this open-label extension (OLE) study with 60% retention at 24 months.”
> “Sustained monthly reduction in seizure frequency (median percentage change 80.2%–83.2%) from baseline was observed during OLE months 12–24.”
> “Seizure freedom for ≥6- and ≥12-month consecutive durations was achieved in 22.2% and 14.9% of OLE participants, respectively.”
> “Seizure freedom for ≥6- and ≥12-month consecutive durations was achieved in 34.5% and 23.6% of those treated for ≥24 months, respectively.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.8.3-11"></a>

###### Open-label extension: 36-month interim results

> “Sustained reductions in seizure frequency: For ongoing OLE patients, monthly median percent change (MPC) reductions in FOS frequency ranged from 61%‑82% during month 1 to OLE study month 24 and were maintained at 85% at OLE study month 36. Patients who were receiving 1 to 2 anti-seizure medications (ASMs) at baseline experienced higher monthly MPC reductions in FOS frequency from baseline at OLE study month 36 (100% seizure reduction, n=67), compared to those receiving 3 ASMs (80.6% seizure reduction, n=80).”
> “Achieving seizure freedom: For those participants who were treated for >36 months in the OLE, 32.7% (48/147) achieved seizure freedom for a period of at least 12 months.”
> “Long-term retention: A total of 182 participants were treated in the OLE for ≥12 months, 165 participants were treated for ≥24 months, and 143 participants were treated for ≥36 months at the time of the analysis cutoff (October 7, 2024). Retention rates with azetukalner at 12, 24, and 36 months into the OLE study period were 66%, 60%, and 52%, respectively.”

Source: [Xenon Pharmaceuticals OLE data release (2024)](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-showcases-new-long-term-azetukalner-data-x-tole-ole-study)

<a id="topic-3.1.1.8.3-12"></a>

###### Open-label extension: 42-month interim analysis

> “The MPC in seizure frequency was −87% for those remaining in OLE at 42 months.”

Source: [French et al. (2025b)](https://aesnet.org/abstractslisting/long-term-safety-and-efficacy-of-azetukalner-a-novel-potent-kv7-potassium-channel-opener-in-adults-with-focal-epilepsy-42-month-interim-analysis-of-the-ongoing-7-year-x-tole-open-label-extension)

<a id="topic-3.1.1.8.3-13"></a>

###### Open-label extension: 48-month interim analysis

> “Sustained reductions in seizure frequency: Among participants treated for ≥48 months in the OLE (n=131), monthly median percent change (MPC) in FOS frequency increased from a 69.8% reduction in the first month of the OLE to a 90.9% reduction at OLE study month 48. At OLE month 48, higher monthly MPC reductions in FOS frequency from the double-blind period (DBP) baseline were observed for participants in the OLE who were receiving 1-2 ASMs at DBP baseline (n=60, 100%) compared with those receiving 3 ASMs (n=69, 81.8%).”
> “Attained seizure freedom: Among the participants treated for ≥48 months in the OLE (n=131), seizure freedom for any ≥12-, ≥24-, ≥36-, and ≥48-month consecutive durations was attained by 38.2%, 25.2%, 19.8% and 10.7% of the participants respectively.”

Source: [Xenon Pharmaceuticals AES 2025 data release (2025)](https://www.globenewswire.com/news-release/2025/12/05/3200741/0/en/Xenon-Showcases-New-48-Month-Azetukalner-OLE-Study-Data-in-Epilepsy-at-AES-2025.html)

<a id="topic-3.1.1.8.3-14"></a>

###### Open-label extension: regaining seizure freedom after a breakthrough seizure

> “Of the 131 participants who were treated in the OLE for ≥48 months who had a breakthrough seizure after one interval, or epoch, of ≥6 consecutive months of seizure freedom in the OLE (n=33), 69.7% (n=23) and 57.6% (n=19) regained ≥6 and ≥12 months of subsequent seizure freedom, respectively, with continued azetukalner treatment. Of the participants who had a breakthrough seizure (n=33), there was a mean duration of regained seizure freedom of 18.9 months.”

Source: [Xenon Pharmaceuticals AES 2025 data release (2025)](https://www.globenewswire.com/news-release/2025/12/05/3200741/0/en/Xenon-Showcases-New-48-Month-Azetukalner-OLE-Study-Data-in-Epilepsy-at-AES-2025.html)

<a id="topic-3.1.1.8.3-15"></a>

###### Open-label extension: characterization of seizure-freedom intervals

> “Of all OLE participants, 137 (49.8%) were treated for ≥42 months as of April 1, 2025. Among them, 26.3% (36/137) had achieved ≥12 months of seizure freedom; of these participants 77.8% (28/36) had ≥24 months and 58.3% (21/36) had ≥36 months seizure freedom from last study visit. 46.7% (64/137) achieved one interval of seizure freedom for any ≥6 consecutive months. Of those participants, 48.4% (31/64) had a subsequent seizure, 71.0% (22/31) regained ≥6 months, and 58.1% (18/31) regained ≥12 months of subsequent seizure freedom. The mean duration of the regained consecutive period of seizure freedom in these 31 participants was 17.5 months (median, 13 months).”

Source: [Becker et al. (2025)](https://aesnet.org/abstractslisting/characterization-of-long-term-seizure-freedom-in-the-ongoing-open-label-extension-of-x-tole-potential-implications-for-future-clinical-practice)

Additional sources: [French et al. (2024)](https://www.neurology.org/doi/10.1212/WNL.0000000000208587)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Clinical and patient global impression of change during the double-blind phase

> “The significant reductions in FOS frequency in patients receiving XEN1101 were associated with improvement in overall health status as assessed by both investigators, using the Clinical Global Impression–Change (CGI-C) scale, and by patients, using the Patient Global Impression–Change (PGI-C) scale. The difference in the percentage of patients who were much improved or very much improved between the placebo vs the 25-mg XEN1101 treatment groups was statistically significant for both the CGI-C (46.4% vs 22.8%; P < .001) and PGI-C (42.9% vs 21.9%; P = .001) (Table 2). In addition, the PGI-C results for the 20-mg dose, although underpowered, were statistically significant (37.3% vs 21.9%; P = .04), and numeric improvements over placebo were noted in the CGI-C for the 20-mg dose and the CGI-C and PGI-C for the 10-mg dose.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.4-2"></a>

###### Quality of Life in Epilepsy Inventory outcomes in the open-label extension at 1.5 years

> “On completion of the double-blind period (DBP), eligible patients transitioned to the OLE at 20 mg QD in the fed state. Beginning at week 15 in the OLE, the QOLIE-31 was completed at three month intervals for the first year, then every six months thereafter. Results are reported for the OLE at 1.5 years compared to the double-blind baseline assessment. Minimally important change (MIC) thresholds in QOLIE-31 scores (Borghs et al. Epilepsy Behav 2012;23:230-4) were applied to the overall group and seizure-free group.”
> “In the interim analysis (data cut April 12, 2023), 170 patients were treated for ≥18 months in the ongoing X-TOLE OLE, and monthly (28-day) FOS median reduction at 18 months was 83.4%. Of these patients, 33 (19.4%) were seizure-free for ≥12 consecutive months. At 1.5 years, QOLIE-31 subscale scores met the MIC threshold for improvement in the overall and seizure-free groups, as follows: overall QoL of 6.4 and 13.2 points, respectively, seizure worry of 12.8 and 23.7 points, and social functioning of 8.3 and 22.3 points. Additionally, for the seizure-free group only, QOLIE-31 subscale scores met the MIC threshold for improvement for energy/fatigue (6.4 points), cognitive functioning (10.6 points), medication effects (15.2), and QOLIE-31 total score (13.1).”

Source: [Brandt et al. (2023)](https://aesnet.org/abstractslisting/long-term-quality-of-life-improvements-in-adults-with-focal-onset-seizures-treated-with-xen1101-in-an-ongoing-open-label-extension-of-a-phase-2b-study-x-tole)

<a id="topic-3.1.1.8.4-3"></a>

###### Quality of life domains improving in the open-label extension at 2 years

> “Clinically important improvements in the Quality of Life in Epilepsy Inventory-31 (QOLIE-31) subscales of Seizure Worry, Social Functioning, and Medication Effects were seen across all patients, with even greater improvements in the seizure-free group (SFG).”
> “The SFG achieved clinically important improvements in all quality-of-life domains assessed by the QOLIE-31 except for Energy/Fatigue.”
> “Quality-of-life improvements, as measured by the QOLIE-31, originally reported at year 1 were maintained or improved at year 2 of the X-TOLE OLE.”

Source: [Xenon Pharmaceuticals neurology pipeline update (2023)](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-provides-updates-neurology-pipeline-0)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Overall tolerability and most common treatment-emergent adverse events

> “The TEAEs are summarized in Table 3. XEN1101 was generally well tolerated in this study, with TEAEs being consistent with other commonly prescribed ASMs. The most common (>10%) TEAEs across all XEN1101 dose groups were dizziness (24.6%), somnolence (15.6%), and fatigue (10.9%). The incidence of TEAEs appeared to be dose related (Table 3). Weight increase as a TEAE was reported in 1 patient (0.9%) receiving placebo, 1 patient (2.2%) at 10 mg, 2 patients (3.9%) at 20 mg, and 3 patients (2.6%) at 25 mg. No TEAEs of tissue discoloration were reported. Two nonserious TEAEs of urinary retention were reported in the active treatment groups, 1 of which required a dose reduction; both patients continued to receive the study medication with no other changes or interventions, including no need for catheterization. The adverse event of confusional state was reported in 4.7% of the treated groups (2.2% receiving 10 mg, 5.9% receiving 20 mg, and 5.3% receiving 25 mg) and in 0.9% of the placebo group. No allergic rashes occurred.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.5-2"></a>

###### Summary of adverse events in the double-blind phase

| Variable | Placebo (n = 114) | XEN1101, 10 mg (n = 46) | XEN1101, 20 mg (n = 51) | XEN1101, 25 mg (n = 114) | XEN1101, any dose (n = 211) |
| --- | --- | --- | --- | --- | --- |
| At least 1 TEAE, No. (%) | “71 (62.3)” | “31 (67.4)” | “35 (68.6)” | “97 (85.1)” | “163 (77.3)” |
| At least 1 serious TEAE, No. (%) | “3 (2.6)” | “2 (4.3)” | “2 (3.9)” | “3 (2.6)” | “7 (3.3)” |
| At least 1 TEAE leading to permanent treatment discontinuation, No. (%) | “4 (3.5)” | “1 (2.2)” | “7 (13.7)” | “18 (15.8)” | “26 (12.3)” |
| At least 1 serious TEAE leading to death, No. (%) | “0” | “0” | “0” | “0” | “0” |
| Nervous system disorders | “35 (30.7)” | “20 (43.5)” | “28 (54.9)” | “83 (72.8)” | “131 (62.1)” |
| Dizziness | “8 (7.0)” | “3 (6.5)” | “13 (25.5)” | “36 (31.6)” | “52 (24.6)” |
| Somnolence | “8 (7.0)” | “5 (10.9)” | “11 (21.6)” | “17 (14.9)” | “33 (15.6)” |
| Headache | “9 (7.9)” | “6 (13.0)” | “6 (11.8)” | “9 (7.9)” | “21 (10.0)” |
| Balance disorder | “2 (1.8)” | “2 (4.3)” | “4 (7.8)” | “13 (11.4)” | “19 (9.0)” |
| Tremor | “2 (1.8)” | “3 (6.5)” | “3 (5.9)” | “12 (10.5)” | “18 (8.5)” |
| Aphasia | “1 (0.9)” | “1 (2.2)” | “1 (2.0)” | “8 (7.0)” | “10 (4.7)” |
| Ataxia | “1 (0.9)” | “3 (6.5)” | “1 (2.0)” | “5 (4.4)” | “9 (4.3)” |
| Dysarthria | “0” | “1 (2.2)” | “0” | “8 (7.0)” | “9 (4.3)” |
| Memory impairment | “1 (0.9)” | “1 (2.2)” | “2 (3.9)” | “6 (5.3)” | “9 (4.3)” |
| Psychiatric disorders | “18 (15.8)” | “7 (15.2)” | “13 (25.5)” | “31 (27.2)” | “51 (24.4)” |
| Confusional state | “1 (0.9)” | “1 (2.2)” | “3 (5.9)” | “6 (5.3)” | “10 (4.7)” |
| Fatigue | “6 (5.3)” | “5 (10.9)” | “4 (7.8)” | “14 (12.3)” | “23 (10.9)” |
| Gait disturbance | “1 (0.9)” | “2 (4.3)” | “2 (3.9)” | “8 (7.0)” | “12 (5.7)” |
| Eye disorders | “6 (5.3)” | “3 (6.5)” | “5 (9.8)” | “18 (15.8)” | “26 (12.3)” |
| Vision blurred | “1 (0.9)” | “0” | “1 (2.0)” | “7 (6.1)” | “8 (3.8)” |

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.5-3"></a>

###### Discontinuations, serious adverse events, and deaths

> “Discontinuation associated with TEAEs occurred in 3.5% of patients receiving placebo, 2.2% of patients receiving 10 mg, 13.7% of patients receiving 20 mg, and 15.8% of patients receiving 25 mg. The most common TEAEs leading to discontinuation across XEN1101 groups were dizziness (4.7%), balance disorder (2.4%), dysarthria (1.9%), and gait disturbance (1.9%). The incidence of serious AEs was low and balanced across treatment groups, occurring in 4.3% of patients receiving 10 mg, 3.9% of patients receiving 20 mg, and 2.6% of patients receiving 25 mg. The incidence of serious AEs in patients receiving placebo (2.6%) was the same as that recorded at the highest dose of XEN1101. There were no deaths in the study.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.5-4"></a>

###### Cardiovascular, laboratory, and body weight findings

> “There were no cardiovascular signals of concern based on vital signs including orthostatic tests, and no safety signals of concern from physical or neurologic examinations. Mean (SD) body weight changes from baseline were 0.2 (2.4) kg in patients receiving placebo, 0.6 (2.3) kg in patients receiving 10 mg, 1.6 (2.2) kg in patients receiving 20 mg, and 1.9 (2.9) kg in patients receiving 25 mg. There were no signals of concern from electrocardiograms, laboratory tests evaluating safety, or urinalysis.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.8.5-5"></a>

###### Absence of pigmentary abnormalities reported by the sponsor

> “There have been no TEAEs of pigmentary abnormalities reported during the double-blind phase of the study or in preliminary analysis during the ongoing open-label extension to date with approximately 70 subjects now treated more than 12 months.”

Source: [Xenon Pharmaceuticals X-TOLE topline release (2021)](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-announces-positive-topline-results-phase)

<a id="topic-3.1.1.8.5-6"></a>

###### Structural basis for the absence of pigmented dimers

> “XEN1101 demonstrates higher in vitro and in vivo potency compared to the first generation Kv7.2-7.5 opener, ezogabine, and lacks the chemical properties that could form pigmented dimers.”

Source: [French et al. (2021)](https://aesnet.org/abstractslisting/phase-2b-efficacy-and-safety-of-xen1101--a-novel-potassium-channel-modulator--in-adults-with-focal-epilepsy-(x-tole))

<a id="topic-3.1.1.8.5-7"></a>

###### Open-label extension: treatment-emergent adverse events at the 24-month interim analysis

> “During the OLE, TEAEs were reported in 240 of 275 participants (87.3%) of the safety population (Table 2). Those reported most commonly (>10% of participants) were dizziness (21.8%), headache (15.3%), coronavirus infection (15.3%), somnolence (12.7%), fall (12.7%), and memory impairment (10.9%). Three participants reported urinary retention, 1 reported it as mild and 2 as moderate; no dose changes were made in any case. TEAEs that led to permanent treatment discontinuation (>2 participants) were dizziness (6 participants, 2.2%), somnolence (4 participants, 1.5%), and amnesia (3 participants, 1.1%). SAEs were reported in 35 participants (12.7%); SAEs reported in >1 participant were change in seizure presentation, reported in 6 participants (2.2%), and paresthesia, seizure, pneumonia aspiration, deep vein thrombosis, and fall, each reported in 2 participants (0.7%). There was 1 sudden unexpected death in epilepsy (SUDEP) reported, which was determined not to be related to the study drug. No signals of cardiovascular safety were identified as of the Sept 5, 2023, cutoff date. Overall, TEAEs were similar to those reported in the DBP, and no new safety signals were identified. At the end of the second year, participants recorded a mean (SD) weight change of −0.2 (8.8) kg.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.8.5-8"></a>

###### Treatment-emergent adverse events during the open-label extension

| Summary of TEAEs, n (%) | Azetukalner 20 mg (n = 275) |
| --- | --- |
| At least 1 TEAE | “240 (87.3)” |
| At least 1 serious TEAE | “35 (12.7)” |
| At least 1 TEAE leading to permanent discontinuation of study drug | “30 (10.9)” |
| At least 1 serious TEAE leading to death | “1 (0.4)” |
| Dizziness | “60 (21.8)” |
| Coronavirus infection | “42 (15.3)” |
| Headache | “42 (15.3)” |
| Fall | “35 (12.7)” |
| Somnolence | “35 (12.7)” |
| Memory impairment | “30 (10.9)” |
| Weight increased | “26 (9.5)” |
| Gait disturbance | “23 (8.4)” |
| Fatigue | “22 (8.0)” |
| Urinary tract infection | “22 (8.0)” |
| Aphasia | “21 (7.6)” |
| Change in seizure presentation | “20 (7.3)” |
| Nasopharyngitis | “17 (6.2)” |
| Confusional state | “16 (5.8)” |
| Disturbance in attention | “15 (5.5)” |
| Balance disorder | “14 (5.1)” |
| Paresthesia | “14 (5.1)” |
| Tremor | “14 (5.1)” |

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.8.5-9"></a>

###### Long-term tolerability conclusions from the extension

> “Safety results from the OLE demonstrate that azetukalner is generally well tolerated during long-term treatment, with a tolerability profile consistent with that reported during the DBP. Besides coronavirus infection and falls, the most commonly reported TEAEs were related to the central nervous system (dizziness, headache, somnolence, and memory impairment). One case of SUDEP has been reported, which was not attributed to treatment.”
> “In total, 10.9% of participants discontinued the OLE due to a TEAE. No new safety signals were observed, and no signals of cardiovascular safety were identified.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.8.5-10"></a>

###### Open-label extension safety at the April 2025 data cut

> “TEAEs were reported in 246 (89.5%) participants; 178 (64.7%) reported a treatment-related TEAE. Most TEAEs were mild or moderate; 49 participants (17.8%) reported severe TEAEs. The most common TEAEs (≥10% of participants) were dizziness (n=64, 23.3%), headache (n=50, 18.2%), COVID-19 infection (n=47, 17.1%), somnolence (n=45, 16.4%), fall (n=39, 14.2%), weight increased (n=31, 11.3%), and memory impairment (n=29, 10.5%). The mean (SD) weight change was 0.78 (9.96) kg and the median (Q1, Q3) was 0 (−3, 4) kg at 3.5 years in the OLE. In total, 43 (15.6%) participants reported ≥1 SAE, of which 7 (2.5%) were considered related to the study drug. Across the entire DBP and OLE study duration, 2 deaths have been reported, 1 due to sudden unexpected death in epilepsy and 1 from viral pneumonia, neither considered treatment related.”

Source: [French et al. (2025b)](https://aesnet.org/abstractslisting/long-term-safety-and-efficacy-of-azetukalner-a-novel-potent-kv7-potassium-channel-opener-in-adults-with-focal-epilepsy-42-month-interim-analysis-of-the-ongoing-7-year-x-tole-open-label-extension)

<a id="topic-3.1.1.8.5-11"></a>

###### Cumulative exposure accrued in the open-label extension

> “Consistent safety and tolerability: As of data cut-off, the OLE has generated more than 775 patient-years of safety and exposure data. Long-term safety of AZK in the OLE was comparable with the safety observed in the X-TOLE DBP.”

Source: [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: limitations of the double-blind phase

The double-blind phase lasted 8 weeks, which the investigators identify as a limitation for assessing long-term safety and efficacy. Group sizes were unequal by design under the 2:1:1:2 randomization ratio, so the 10 mg group (n = 46) and 20 mg group (n = 51) were smaller than the placebo and 25 mg groups (n = 114 each), and the investigators note that the 20 mg analysis of global impression of change was underpowered. The investigators state that the effect of the COVID-19 pandemic on study outcomes is unknown and that pandemic restrictions on site access may have contributed to enrollment of a more refractory population, characterized by a median of 13.5 seizures per month and a median of 6 previously stopped antiseizure medications. Race was recorded but 298 of 325 participants (91.7%) identified as White, with less than 4% representation in any other category, so the investigators state that analysis by race would not contribute to a meaningful analysis in this single study. Seizure freedom rates derived from the 8-week treatment period were low in absolute terms, at 6.3% for 25 mg, 7.8% for 20 mg, 2.2% for 10 mg, and 1.8% for placebo among all observed participants.

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.9-2"></a>

###### Summary: limitations of the open-label extension

The open-label extension has no control group and no blinding, and the investigators note potential selection bias because not all participants who enrolled in the double-blind phase entered the extension, although 275 of 285 completers (96.5%) did so. Long-term efficacy estimates can be biased by dropout, because participants who perceive benefit may preferentially remain on treatment; retention was 60% at 24 months, with 13.8% discontinuing for lack of efficacy and 12.0% for adverse events. The investigators report that a constant-cohort analysis restricted to participants treated for at least 24 months produced comparable improvements, indicating that the improvement is not solely attributable to attrition bias. Comparisons against extension studies of other antiseizure medications are limited by differing methods and treatment durations. The data are interim: the extension is scheduled to run 378 weeks, or 7 years, and no participant had completed it at the time of the publication.

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.9-3"></a>

###### Limitations stated by the investigators for the double-blind phase

> “Study limitations include the relatively short 8-week treatment duration; however, analysis of participants in the ongoing open-label extension phase is expected to provide insight into the long-term safety and efficacy of XEN1101. There were fewer individuals in the 10- and 20-mg groups compared with the placebo and 25-mg groups; nevertheless, a clear dose response was demonstrated. It is unknown what the impact of COVID-19 was on study outcomes. It is possible that general pandemic restrictions on site access may have contributed to enrollment of a more refractory population (ie, medians of 13.5 seizures/month and 6 previously stopped ASMs).”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.9-4"></a>

###### Limitation on analysis by race

> “The US Food and Drug Administration expects race to be collected as a covariate across the development program. With less than 4% representation in any other race category, analysis by race would not contribute to a meaningful analysis in this single study.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-3.1.1.9-5"></a>

###### Limitations stated by the investigators for the open-label extension

> “OLE trials, such as this study, have inherent limitations that must be considered when interpreting the results. Key limitations are the open-label design and lack of a control group. In addition, there could also be selection biases since not all participants who enrolled in the DBP entered the OLE phase. This limitation is mitigated in the present situation by the fact that nearly all eligible subjects chose to receive double-blind treatment, and almost all (96%) of those completing the DBP continued into the OLE.”
> “As in all OLE studies, long-term assessment can be biased by participant dropout during the course of the OLE. Participants who perceive that they are doing well may preferentially remain on treatment. Moreover, at 24 months in the OLE, retention on azetukalner remained high at 60%, with only 13.8% and 12.0% of participants discontinuing the study due to lack of efficacy and due to AEs, respectively. In addition, our analysis of efficacy outcomes in a constant cohort group shows comparable improvements, indicating that the improvement is not solely due to attrition bias.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-3.1.1.9-6"></a>

###### Limitation of cross-study comparison of seizure freedom rates

> “While it is difficult to compare seizure freedom rates across studies due to different methodologies and study durations, other OLE studies have reported on seizure freedom rates.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="heading-3.1.2"></a>

#### 3.1.2 X-TOLE2

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Trial objective: adjunctive azetukalner in focal onset seizures

> “The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.1-2"></a>

###### Sponsor description of the study

> “The X-TOLE2 clinical trial (NCT05614063) was a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the efficacy, safety, and tolerability of azetukalner, administered as an oral, adjunctive therapy once-daily with food in adult patients with FOS.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Summary: sponsor, identifiers, sites, and study dates

The registry record for NCT05614063 gives Xenon Pharmaceuticals Inc. as lead sponsor, Worldwide Clinical Trials as collaborator, and XPF-010-301 as the sponsor protocol number. The actual study start date was 18 November 2022, the actual primary completion date was 12 January 2026, and the actual study completion date was 3 February 2026. The record lists 125 study locations across 18 countries: the United States (56 sites), Spain (10), Australia (9), Argentina (8), Germany (8), the United Kingdom (7), Italy (4), Poland (4), Canada (3), Portugal (3), Chile (2), Georgia (2), Latvia (2), Mexico (2), New Zealand (2), Bulgaria (1), Czechia (1), and Ireland (1).

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.2-2"></a>

###### Announcement of topline results

> “VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS).”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Randomization, baseline period, and double-blind period

> “Approximately 360 subjects will be randomized in a blinded manner to one of two active treatment groups or placebo in a 1:1:1 fashion (XEN1101 25 mg : 15 mg : Placebo). Eligible subjects will have up to 9.5 weeks of baseline to assess frequency of seizures, followed by 12 weeks of blinded treatment. In order to be included in the study, subjects must be treated with a stable dose of 1 to 3 allowable antiseizure medications (ASMs) for at least one month prior to screening, during baseline, and throughout the double-blind treatment period (DBP) of the study. During the DBP, subjects will be instructed to orally take XEN1101 or placebo once daily with an evening meal.”
> “Subjects who complete the 12-week DBP will have the opportunity to qualify and enroll in a separate open-label extension (OLE) study for continued treatment with XEN1101. Subjects who do not enroll in the OLE will enter a 8-week post treatment follow-up period.”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.3-2"></a>

###### Design as described by the sponsor at congress presentation

> “X-TOLE2 was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the clinical efficacy, safety, and tolerability of AZK as adjunctive treatment in adults with FOS over a 12-week double-blind period (DBP).”

Source: [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html)

<a id="topic-3.1.2.3-3"></a>

###### Design shared with the second Phase 3 focal seizure study

> “The completed X-TOLE2 study and the ongoing X-TOLE3 study were both designed as multicenter, randomized, double-blind, placebo-controlled studies to evaluate the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients per study with FOS.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Summary: age and sex eligibility

The registry record sets a minimum age of 18 years, accepts participants of all sexes, and does not accept healthy volunteers.

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.4-2"></a>

###### Inclusion criteria

> “Diagnosis (≥2 years) of focal epilepsy according to the International League Against Epilepsy (ILAE) Classification of Epilepsy (2017). Subject must have had adequate trials of at least 2 ASMs, which were given (and tolerated) at adequate therapeutic doses, without achieving sustained seizure freedom.”
> “Treatment with a stable dose of 1 to 3 allowable current ASMs for at least one month prior to screening, during baseline, and throughout the duration of the DBP”
> “Able to keep accurate seizure diaries”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.4-3"></a>

###### Exclusion criteria

> “Previously documented electroencephalogram which shows any pattern not consistent with focal etiology of seizures.”
> “History of focal aware non-motor seizures only, non-epileptic psychogenic seizure, primary generalized seizure, developmental and epileptic encephalopathy, including Lennox-Gastaut syndrome.”
> “Seizures secondary to drug or alcohol use, ongoing infection, neoplasia, demyelinating disease, degenerative neurological disease, metabolic illness, progressive structural lesion, encephalopathy, or progressive central nervous system (CNS) disease.”
> “History of status epilepticus or repetitive seizures within the 12-month period preceding Visit 1 where the individual seizures cannot be counted.”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Summary: study arms and interventions

Participants were randomized in a 1:1:1 ratio to azetukalner 25 mg per day, azetukalner 15 mg per day, or placebo. The investigational product is recorded in the registry as XEN1101 capsules, with azetukalner given as the other name, and the comparator as placebo capsules.

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.5-2"></a>

###### Administration once daily with an evening meal

> “During the DBP, subjects will be instructed to orally take XEN1101 or placebo once daily with an evening meal.”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.5-3"></a>

###### No titration required

> “The data also continue to support a differentiated clinical profile for azetukalner relative to other antiseizure medications, including no need for titration, once-daily dosing, and no meaningful drug-drug interactions.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Median Percent Change in Monthly Focal Onset Seizure Frequency as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Summary: rationale for the primary endpoint

Median percent change in monthly seizure frequency from baseline through the 12-week double-blind period is the primary efficacy endpoint used across the Phase 3 epilepsy trials of azetukalner. The same measure was the primary endpoint of the Phase 2b X-TOLE trial, which allows the placebo-adjusted effect sizes of the two focal seizure trials supporting the New Drug Application to be compared directly.

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html); [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.6.1-2"></a>

###### Primary outcome measure

> “Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo.”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.6.1-3"></a>

###### Secondary outcome measures

> “Proportion of subjects experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline through the DBP for XEN1101 versus placebo.”
> “MPC in weekly (7 days) focal seizure frequency from baseline to Week 1 for XEN1101 versus placebo.”
> “Proportion of subjects experiencing "at least much improved" (including "much" and "very much improved") in Patient Global Impression of Change (PGI-C).”
> “To assess adverse events as criteria for safety and tolerability of XEN1101”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.6.1-4"></a>

###### Outcome time frames

> “From baseline through to the double blind period (week 12)”
> “From screening through to 56 days post-final dose.”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.6.1-5"></a>

###### Primary efficacy endpoint definition used across the Phase 3 epilepsy trials

> “The primary efficacy endpoint is median percent change (MPC) in monthly seizure frequency from baseline through the 12-week double-blind period (DBP) of azetukalner compared to placebo.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment

> “Approximately 360 subjects will be randomized in a blinded manner to one of two active treatment groups or placebo in a 1:1:1 fashion (XEN1101 25 mg : 15 mg : Placebo).”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.7.1-2"></a>

###### Participants randomized and analyzed

> “The study randomized participants in a blinded manner to either azetukalner 25 mg, 15 mg, or placebo, and included a total of 380 randomized participants, with 374 participants in the safety and modified intent-to-treat (mITT) population for the safety and efficacy analyses.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants analyzed per treatment group

| Treatment group | Quoted record |
| --- | --- |
| Azetukalner 25 mg | “Azetukalner 25 mg (n=124)” |
| Azetukalner 15 mg | “Azetukalner 15 mg (n=125)” |
| Placebo | “Placebo (n=125)” |

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Safety and modified intention-to-treat populations

> “with 374 participants in the safety and modified intent-to-treat (mITT) population for the safety and efficacy analyses”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Completion of the double-blind period and entry into the open-label extension

> “Of the 332 participants who completed the double-blind period, 322 entered the open-label extension study.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-3.1.2.8.1-2"></a>

###### Discontinuation due to treatment-emergent adverse events

> “14.5% of participants in the 25 mg group, 4.8% in the 15 mg group, and 3.2% in the placebo group had a TEAE leading to treatment discontinuation.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Treatment resistance, seizure burden, and concomitant antiseizure medications

> “Participants had highly treatment-resistant epilepsy, with a median of five prior ASMs, a baseline seizure frequency of 12.75 per month, and 51.3% using three concomitant ASMs.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-3.1.2.8.2-2"></a>

###### Prior and concomitant cenobamate use

> “Participants had highly treatment-resistant epilepsy, with a median baseline seizure frequency of 12.75 per month, a median of five prior anti-seizure medications (ASMs), and 51.3% using three concomitant ASMs. Approximately 40% of participants entering the study were taking concomitant cenobamate, while 19% had previously tried and discontinued cenobamate.”
> “These data are particularly striking considering nearly 60% of the patient population were taking or had already discontinued cenobamate and were experiencing a high seizure burden with a median of 13 seizures per month at baseline.”

Source: [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Primary endpoint: median percent change in monthly focal onset seizure frequency

> “The study met its primary endpoint of MPC in monthly FOS frequency from baseline to week 12 in both the 25 mg and 15 mg azetukalner dose groups compared to placebo [MPC of -53.2% (p=0.000000000006), -34.5% (p=0.00007) and -10.4%, respectively].”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-3.1.2.8.3-2"></a>

###### Primary and key secondary endpoint results by treatment group

| Endpoint | Azetukalner 25 mg (n=124) | Azetukalner 15 mg (n=125) | Placebo (n=125) |
| --- | --- | --- | --- |
| Median percent change in monthly focal onset seizure frequency, baseline to week 12 | “-53.2% (p=0.000000000006)” | “-34.5% (p=0.00007)” | “-10.4%” |
| Proportion with at least a 50 percent reduction in monthly focal onset seizure frequency | “54.8%” | “37.6%” | “20.8%” |

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-3.1.2.8.3-3"></a>

###### Placebo-adjusted effect compared with the Phase 2b trial

> “The placebo-adjusted MPC in the 25 mg group was -42.7%, outperforming the previously completed Phase 2b X-TOLE study, which demonstrated a -34.6% placebo-adjusted MPC in the 25 mg dose group over 8 weeks (-52.8% in the 25 mg group and -18.2% in the placebo group).”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-3.1.2.8.3-4"></a>

###### Key secondary endpoint: 50 percent responder rate

> “In addition to meeting the primary endpoint of MPC in monthly FOS frequency, the study also met the key secondary endpoint of Responder Rate 50 (RR50), with 54.8% in the 25 mg group and 37.6% in the 15 mg group experiencing at least a 50% reduction in monthly FOS frequency from baseline, compared with 20.8% in the placebo group (p=0.00000008 and p=0.003 for 25 mg and 15 mg groups, respectively).”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-3.1.2.8.3-5"></a>

###### Onset of effect at week 1 and dose-dependent responder rates

> “Early and significant reductions in seizure frequency (Median Percent Change in FOS): Treatment with 25 mg or 15 mg AZK resulted in a statistically significant -53.2% or -34.5% Median Percent Change (MPC), respectively, from baseline through the DBP in monthly FOS, compared to a -10.4% MPC for placebo (p<0.0001 for both 25 and 15 mg vs. placebo). Dose-dependent MPC reductions in weekly FOS were observed from baseline to week 1, which were sustained through the DBP with both AZK doses.”
> “Dose-dependent increase in 50%, 75%, and 90% Responder Rates: There was a statistically significant, dose-dependent increase in the proportion of participants with a ≥50% reduction in monthly seizure frequency from baseline through the DBP. Dose-dependent increases in the proportion of participants with a ≥75% and a ≥90% reduction in monthly seizure frequency were also observed.”

Source: [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html)

<a id="topic-3.1.2.8.3-6"></a>

###### Seizure freedom over the double-blind period

> “Improvements in 100% Responder Rate observed over time: A 100% reduction in monthly FOS frequency from baseline through the DBP was attained by a greater proportion of participants with AZK 25 mg than with placebo (6.5% vs. 0.8%, respectively; nominal p<0.05). A post hoc analysis showed that a greater proportion of participants achieved a 100% Responder Rate over time with AZK in the last eight, six and four weeks of the DBP (nominal p<0.05) as AZK reached steady-state levels.”
> “Last 8 weeks: 25 mg: 10.5%, 15 mg: 5.6%, placebo: 2.4%”
> “Last 6 weeks: 25 mg: 11.3%, 15 mg: 8.0%, placebo: 4.0%”
> “Last 4 weeks: 25 mg: 13.7%, 15 mg: 12.8%, placebo: 4.0%”

Source: [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html)

<a id="topic-3.1.2.8.3-7"></a>

###### Investigator characterization of the magnitude of effect

> “In X-TOLE2, azetukalner demonstrated the best placebo-adjusted efficacy ever observed in a pivotal FOS study, to our knowledge.”

Source: [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### Patient Global Impression of Change as a prespecified secondary endpoint

> “Proportion of subjects experiencing "at least much improved" (including "much" and "very much improved") in Patient Global Impression of Change (PGI-C).”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-3.1.2.8.4-2"></a>

###### Reported patient-reported outcome results

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Most common treatment-emergent adverse events

> “The most common treatment-emergent adverse events (TEAEs) across both azetukalner dose groups were dizziness (20.5%), headache (8.8%), somnolence (8.8%), and fatigue (7.6%) as compared to the placebo group, which reported dizziness (3.2%), headache (6.4%), somnolence (7.2%), and fatigue (6.4%).”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-3.1.2.8.5-2"></a>

###### Serious treatment-emergent adverse events

> “The incidence of serious TEAEs was low and similar across treatment groups, with 5.6% in the 25 mg group, 3.2% in the 15 mg group, and 2.4% in the placebo group experiencing a serious TEAE.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-3.1.2.8.5-3"></a>

###### Adverse events of special interest not observed during the double-blind period

> “No notable weight gain, severe allergic rashes, retinal pigment epithelium or macular abnormalities, or notable cardiovascular adverse events occurred during the DBP. These results are consistent with the Phase 2b X-TOLE safety and tolerability results.”

Source: [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html)

<a id="topic-3.1.2.8.5-4"></a>

###### Consistency with the Phase 2b safety profile

> “The safety and tolerability profile of azetukalner remains consistent with the previously disclosed data from the X-TOLE study.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-3.1.2.8.5-5"></a>

###### Cumulative exposure across the epilepsy trials

> “These safety results are comparable with the long-term safety observed in the X-TOLE open label extension (OLE) study, with the entire epilepsy program generating more than 1,500 patient-years of safety and exposure data.”
> “We remain very confident in the product profile of azetukalner as a potential new treatment option for patients with epilepsy based on strong efficacy and safety data and a consistent safety profile across over 1,500 patient-years of data,”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: limitations of the available X-TOLE2 evidence

As of September 2026, X-TOLE2 results are available only from company press releases and congress presentations. No peer-reviewed publication and no ClinicalTrials.gov results record have been posted, so treatment-group-level baseline characteristics, confidence intervals, the statistical testing hierarchy, and full adverse event tables are not publicly available. The double-blind period was 12 weeks, so durability of effect beyond that interval is inferred from a separate open-label extension rather than from randomized comparison. Enrollment was restricted to adults aged 18 years and older with focal epilepsy of at least 2 years duration who had failed at least 2 prior antiseizure medications and were taking 1 to 3 concomitant antiseizure medications, which limits generalizability to monotherapy use, to adolescents and children, and to newly diagnosed epilepsy. The reported analyses of the 100% responder rate over the last 8, 6, and 4 weeks of the double-blind period were post hoc and used nominal p-values. Patient Global Impression of Change was a prespecified secondary endpoint, but no results have been disclosed. Exact p-values differ between company statements, with the March 2026 topline release reporting p=0.000000000006 and p=0.00007 and the April 2026 congress release reporting p<0.0001 for both doses.

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html); [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html); [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="heading-3.1.3"></a>

#### 3.1.3 X-TOLE3

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Trial objective: second Phase 3 trial of adjunctive azetukalner in focal onset seizures

> “The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.”

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)

<a id="topic-3.1.3.1-2"></a>

###### Regulatory purpose stated by the sponsor

> “The Phase 3 X-TOLE3 study of azetukalner in FOS continues to enroll and is intended to support regulatory submissions outside of the United States. X-TOLE3 enrollment outside of Japan is expected to complete in 2026.”

Source: [Xenon Pharmaceuticals Q2 2026 results release (2026)](https://www.globenewswire.com/news-release/2026/08/06/3340663/33485/en/xenon-reports-q2-2026-financial-results-and-provides-business-update.html)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Summary: sponsor, identifiers, sites, and study dates

The registry record for NCT05716100 gives Xenon Pharmaceuticals Inc. as lead sponsor and XPF-010-302 as the sponsor protocol number, with an overall status of recruiting. The actual study start date was 9 May 2023, with estimated primary completion in October 2026 and estimated study completion in December 2026. The record lists 95 study locations across 20 countries: the United States (19 sites), Argentina (12), Portugal (8), Australia (6), France (6), Croatia (5), Poland (5), Chile (4), Israel (4), Mexico (4), Spain (4), Austria (3), Czechia (3), Germany (3), Belgium (2), Bulgaria (2), Italy (2), Finland (1), Hungary (1), and the Netherlands (1).

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Randomization, baseline period, and double-blind period

> “Approximately 360 subjects will be randomized in a blinded manner to one of two active treatment groups or placebo in a 1:1:1 fashion (XEN1101 25 mg : 15 mg : Placebo). Eligible subjects will have up to 9.5 weeks of baseline to assess frequency of seizures, followed by 12 weeks of blinded treatment. In order to be included in the study, subjects must be treated with a stable dose of 1 to 3 allowable antiseizure medications (ASMs) for at least one month prior to screening, during baseline, and throughout the double-blind treatment period (DBP) of the study. During the DBP, subjects will be instructed to orally take XEN1101 or placebo once daily with an evening meal.”
> “Subjects who complete the 12-week DBP will have the opportunity to qualify and enroll in a separate open-label extension (OLE) study for continued treatment with XEN1101. Subjects who do not enroll in the OLE will enter a 8-week post treatment follow-up period.”

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)

<a id="topic-3.1.3.3-2"></a>

###### Design shared with X-TOLE2 as described by the sponsor

> “The completed X-TOLE2 study and the ongoing X-TOLE3 study were both designed as multicenter, randomized, double-blind, placebo-controlled studies to evaluate the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients per study with FOS.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Inclusion criteria

> “Diagnosis (≥2 years) of focal epilepsy according to the International League Against Epilepsy (ILAE) Classification of Epilepsy (2017). Subject must have had adequate trials of at least 2 ASMs, which were given (and tolerated) at adequate therapeutic doses, without achieving sustained seizure freedom.”
> “Treatment with a stable dose of 1 to 3 allowable current ASMs for at least one month prior to screening, during baseline, and throughout the duration of the DBP”
> “Able to keep accurate seizure diaries”

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)

<a id="topic-3.1.3.4-2"></a>

###### Exclusion criteria

> “Previously documented electroencephalogram which shows any pattern not consistent with focal etiology of seizures.”
> “History of focal aware non-motor seizures only, non-epileptic psychogenic seizure, primary generalized seizure, developmental and epileptic encephalopathy, including Lennox-Gastaut syndrome.”
> “History of status epilepticus or repetitive seizures within the 12-month period preceding Visit 1 where the individual seizures cannot be counted.”

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Summary: study arms and interventions

Participants are randomized in a 1:1:1 ratio to azetukalner 25 mg per day, azetukalner 15 mg per day, or placebo. The registry records the investigational product as XEN1101 capsules, with azetukalner given as the other name, and the comparator as placebo capsules.

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Median Percent Change in Monthly Focal Onset Seizure Frequency as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary outcome measure

> “Median percent change (MPC) in focal seizure frequency from baseline to DBP for XEN1101 versus placebo.”

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)

<a id="topic-3.1.3.6.1-2"></a>

###### Secondary outcome measures

> “Proportion of subjects experiencing ≥50% reduction in focal seizure frequency from baseline through the DBP for XEN1101 versus placebo.”
> “MPC in weekly (7 days) focal seizure frequency from baseline to Week 1 for XEN1101 versus placebo.”
> “Proportion of subjects experiencing "at least much improved" (including "much" and "very much improved") in Patient Global Impression of Change (PGI-C).”
> “To assess adverse events as criteria for safety and tolerability of XEN1101.”

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)

<a id="topic-3.1.3.6.1-3"></a>

###### Primary efficacy endpoint shared with X-TOLE2

> “The primary efficacy endpoint is median percent change (MPC) in monthly seizure frequency from baseline through the 12-week double-blind period (DBP) of azetukalner compared to placebo.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned randomization ratio and enrollment

> “Approximately 360 subjects will be randomized in a blinded manner to one of two active treatment groups or placebo in a 1:1:1 fashion (XEN1101 25 mg : 15 mg : Placebo).”

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)

<a id="topic-3.1.3.7.1-2"></a>

###### Planned enrollment in Japan

> “Xenon has aligned with PMDA to enroll approximately 60 of the planned 360 X-TOLE3 participants in Japan.”

Source: [Xenon Pharmaceuticals J.P. Morgan Healthcare Conference release (2026)](https://www.globenewswire.com/news-release/2026/01/12/3216905/0/en/xenon-outlines-key-upcoming-milestones-at-the-2026-j-p-morgan-healthcare-conference.html)

<a id="topic-3.1.3.7.1-3"></a>

###### Participants analyzed

No evidence found.

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Patient Global Impression of Change as a prespecified secondary endpoint

> “Proportion of subjects experiencing "at least much improved" (including "much" and "very much improved") in Patient Global Impression of Change (PGI-C).”

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary: status of the X-TOLE3 evidence

X-TOLE3 is ongoing and recruiting, with estimated primary completion in October 2026 and estimated study completion in December 2026. No efficacy, safety, disposition, or baseline data have been reported. The trial is intended to support regulatory submissions outside the United States rather than the United States New Drug Application, which was submitted on the basis of X-TOLE and X-TOLE2. Enrollment outside Japan is expected to complete in 2026, which implies that Japanese enrollment continues beyond that date and that the full dataset will read out later than the primary completion estimate.

Source: [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100); [Xenon Pharmaceuticals Q2 2026 results release (2026)](https://www.globenewswire.com/news-release/2026/08/06/3340663/33485/en/xenon-reports-q2-2026-financial-results-and-provides-business-update.html); [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="heading-3.1.4"></a>

#### 3.1.4 X-TOLE4

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Open-label extension of the Phase 3 epilepsy trials

> “This is an Open Label Extension study of the following Phase 3 clinical studies: XPF-010-301 (X-TOLE2), XPF-010-302 (X-TOLE3), and XPF-010-303 (X-ACKT). This study will evaluate the long-term safety, tolerability, PK, and efficacy of XEN1101 in subjects with FOS or PGTCS for the treatment of seizures for up to 6 years. Subjects who successfully completed and did not terminate early from one of the antecedent studies (X-TOLE2, X-TOLE3, or X-ACKT) are eligible to participate in X-TOLE4.”

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)

<a id="topic-3.1.4.1-2"></a>

###### Extension available to Phase 3 completers

> “Upon completion of the DBP in the Phase 3 epilepsy studies, eligible patients may enter an open-label extension (OLE) study for up to six years.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Summary: identifiers, dates, and enrollment

The registry record for NCT05718817 gives XPF-010-304 as the sponsor protocol number and X-TOLE4 as the acronym, with an overall status of enrolling by invitation. The actual study start date was 25 April 2023, with estimated primary completion in April 2033 and estimated study completion in June 2033. Estimated enrollment is 880 participants, with a minimum age of 12 years.

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Duration and visit schedule

> “Following enrollment into X-TOLE4, subjects will undergo a treatment period of up to 6 years, during which there will be a visit at 2-, 4-, and 13-weeks post-entry, with subsequent visits occurring at 13-week intervals during the first year, and then at 26-week intervals (with a telephone call in between) until dosing is completed.”

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)

<a id="topic-3.1.4.3-2"></a>

###### Long-term objectives

> “This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years.”

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Eligibility limited to completers of the antecedent Phase 3 studies

> “Subjects who successfully completed and did not terminate early from one of the antecedent studies (X-TOLE2, X-TOLE3, or X-ACKT) are eligible to participate in X-TOLE4.”

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Dosing and seizure diary compliance

> “Subjects will be instructed to orally take XEN1101 once daily (QD) with an evening meal. Subjects will be expected to keep a daily seizure eDiary with a minimum of 80% compliance for the duration of the extension study (reporting on ≥80% of days between visits).”

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Percent Change in Monthly Seizure Rate as a Secondary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Outcome measures in the extension

> “To assess the safety and tolerability of XEN1101”
> “Percent change in monthly seizure rate recorded at baseline (in the antecedent studies) compared to each 4-week assessment period in the treatment period in X-TOLE4.”
> “Proportion of responders (subjects experiencing ≥50% reduction in seizure frequency from baseline) in each consecutive 4-week assessment period of the treatment period of the OLE study.”
> “Change in the 31-Item Quality of Life in Epilepsy Inventory (QOLIE-31) over time.”

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Summary: planned enrollment

The registry record gives an estimated enrollment of 880 participants drawn from the completers of X-TOLE2, X-TOLE3, and X-ACKT. Of the 332 participants who completed the X-TOLE2 double-blind period, 322 entered the open-label extension study.

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817); [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Entry from the X-TOLE2 double-blind period

> “Of the 332 participants who completed the double-blind period, 322 entered the open-label extension study.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

###### Quality of Life in Epilepsy Inventory as a prespecified outcome measure

> “Change in the 31-Item Quality of Life in Epilepsy Inventory (QOLIE-31) over time.”

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary: status of the X-TOLE4 evidence

X-TOLE4 is an open-label extension with no control group and no blinding, enrolling by invitation from the completers of X-TOLE2, X-TOLE3, and X-ACKT. Estimated primary completion is April 2033, and no efficacy, safety, disposition, or baseline data have been reported. Because participants from three antecedent trials with two different seizure types are pooled, outcomes reported from this study will not be specific to focal onset seizures unless reported separately by antecedent trial.

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)

## Related pages
- [Azetukalner (XEN1101): Focal onset seizures](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures.md)
- [Azetukalner (XEN1101) in Focal onset seizures: Terms and abbreviations](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/terms-and-abbreviations.md)
- [Azetukalner (XEN1101): Focal onset seizures](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/executive-summary) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/executive-summary.md)
- [Azetukalner (XEN1101) in Focal onset seizures: Product information and disease description](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/product-information-and-disease-description.md)
- [Azetukalner (XEN1101) in Focal onset seizures: Economic information and modeling report](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/economics) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/economics.md)
- [Azetukalner (XEN1101) in Focal onset seizures: References](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/references) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/references.md)
- [Azetukalner (XEN1101) in Focal onset seizures: prevalence by geography](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/prevalence) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/prevalence.md)
- [Azetukalner (XEN1101) in Focal onset seizures: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/cost-effectiveness-analyses.md)
